AU2002310212A1 - Method and composition for enhancing sexual desire - Google Patents
Method and composition for enhancing sexual desireInfo
- Publication number
- AU2002310212A1 AU2002310212A1 AU2002310212A AU2002310212A AU2002310212A1 AU 2002310212 A1 AU2002310212 A1 AU 2002310212A1 AU 2002310212 A AU2002310212 A AU 2002310212A AU 2002310212 A AU2002310212 A AU 2002310212A AU 2002310212 A1 AU2002310212 A1 AU 2002310212A1
- Authority
- AU
- Australia
- Prior art keywords
- dietary supplement
- ginseng
- administering
- arginine
- daily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
METHOD AND COMPOSITION FOR ENHANCING SEXUAL DESIRE BACKGROUND OF THE INVENTION
This invention relates to the maintenance of a state of wellness in which sexual health is improved.
Quality of life is increasingly valued in today' s society. Proper nutrition and exercise, and healthy sexual function contribute to maintain an overall state of well being, which can serve to manage stress, maintain a properly functioning immune system, protect against disease, maintain a positive mental outlook, and generally to enable one to feel good and enjoy life.
SUMMARY OF THE INVENTION
It has been found that the combination of L-arginine, ginseng, and optionally, ginkgo biloba when administered to a human in combination improves the blood circulation and improves the sexual, mental, and cardiac health of an individual. The invention provides methods and compositions for maintaining a state of wellness in an animal by providing a dietary supplement comprising L-arginine, in combination with ginseng and optionally ginkgo biloba and/or additional nutritional supplements. The invention provides a unique blend of components that, in combination, synergistically bestow sexual wellness upon an animal when taken regularly as a dietary supplement alone, or in combination with a pharmaceutical composition which facilitates smooth muscle relaxation and vascular dilatation.
One aspect of the invention is a composition for improving sexual fitness in an animal. The composition comprises (a) a metabolic precursor to nitric oxide, (b) a material for increasing nitric oxide synthase activity, and optionally (c) a material to promote vascular circulation, particularly microvascular circulation. Additional dietary supplements such as vitamins and minerals can also be included.
Another aspect of the invention is a method for improving sexual function in an animal. The method comprises administering the composition described above.
, A third aspect of the invention is a method of treating sexual dysfunction in a male or female, e.g., erectile dysfunction in the male. The method comprises administering the composition described above.
Yet another aspect of the invention is a method for preparing a composition useful for improving sexual fitness. The process comprises combining the components of the composition described above, preferably into unit dosage forms .
A fifth aspect of the invention is an article of manufacture comprising the composition described above in combination with labeling that the composition is to be taken for sexual fitness.
Table A
A composition of this invention can be specifically tailored for either men or women. For example, a composition for men can have about 250 mg to about 750 mg arginine and about 15 mg to about 50 mg ginseng, preferably about 300 mg to about 600 mg arginine and about 20 mg to about 40 mg ginseng, whereas a composition for women can have about 200 mg to about
600 mg arginine and about 10 mg to about 25 mg ginseng, preferably about 300 mg to about 500 mg arginine and about 15 mg to about 20 mg ginseng. As another example, a composition for a man can comprise American ginseng and Korean ginseng, whereas a composition for a woman can comprise Korean ginseng but not American ginseng. In addition, a composition for a man may have a higher percentage of zinc and selenium, whereas a composition for a woman may have a higher percentage of calcium and iron. Furthermore, the composition can further comprise about 0 mg to about 50 mg damiana, preferably about 5 mg to about 15 mg, particularly for a composition for a woman.
Where the dietary supplement of this invention is an aqueous composition, it may be administered as single or multiple drinks having a volume of up to 500 milliliters (ml) or more. Preferably however it is prepared as a drink having a volume of about 50 to about 300 ml with appropriate flavoring to be consumed either as a cold or hot beverage . Preferably it is flavored with a sweetener and a flavoring agents for easier consumption. A daily dose of two drinks each of about 100 ml has been found to be particularly useful. Table B sets forth the broad, preferred, and most preferred amounts in which the constituents are ' combined to form a unit dosage of 100 ml.
Table B
A preferred composition for a man comprises about 500 to about 10000 mg arginine and about 25 to about 600 mg ginseng, preferably about 100 to about 400 mg ginseng, most preferably about 150 to about 250 mg ginseng.
It should be appreciated that some vitamins and minerals, particularly some of the fat soluble vitamins, zinc, and selenium can be harmful in large doses. Thus, preferably the daily dosage of such vitamins and minerals should not exceed 200% Daily Values. If present, preferred daily dosages of the preferred minerals include about 15-30 mg zinc and about 70 meg to about 140 meg selenium. Preferred daily dosages of the preferred vitamin antioxidants include about 5000 IU to about 10000 IU Vitamin A, about 60 mg to about 120 mg Vitamin C, and about 30 IU to about 60 IU Vitamin E. Preferred daily dosages of the preferred B-vitamins include about 1.5 mg to about 3 mg thiamin, about 1.7 mg to about 3.4 mg riboflavin, about 2 mg to about 4 mg Vitamin B-6, and about 6 meg to about 12 meg Vitamin B-12. Preferred dosages of some other preferred vitamins include about 20 mg to about 40 mg niacin, about 400 meg to about 800 meg folate, about 300 meg to about 600 meg biotin, and about 10 mg to about 20 mg pantothenic acid.
The dietary supplement can be administered in tablet, capsule, liquid, powder, nutritional bar or effervescent form. Methods of preparation of formulations for various forms of administration are known in the art and discussed in detail in Remington' s Pharmaceutical Sciences, Eighteenth Edition (1990) , incorporated herein by reference. Tablets, for example, can include components in addition to the active ingredients, such as diluents, binders, lubricants, glidants, disintegrants, coloring agents, and flavoring agents. Capsules, for example, are made largely from gelatin, FD&C colorants, and sometimes an opacifying agent such as titanium dioxide. Effervescent tablets, for example, comprise in addition to the active ingredients, sodium bicarbonate and an organic acid such as tartaric acid or citric acid. In the presence of water, these additives react, liberating carbon dioxide as a result of an
acid-base reaction, which acts as a disintegrator and produces effervescence. Concentrations of the additives vary according to the acidic or basic nature of the active ingredients in order to ensure that an acid-base reaction occur upon contact of the effervescent tablet with water. The dietary supplement can also be formulated as a powder, which can be ingested directly or which can be ingested after reconstitution with an aqueous liquid. Preferably the supplement is administered in a capsule, effervescent tablet, or as a liquid tonic. The formulations can also comprise a flavoring agent.
Method of Administration
Another aspect of this invention is a method for improving sexual fitness in an animal, particularly human subject. The method comprises administering as unit dosage a composition of the invention, e.g., as a dietary supplement comprising the combination of L-Arginine, ginseng, and optionally ginkgo biloba. '
The regular administration of the composition over time results in improved sexual fitness, i.e., sexual function, in both males and females. Sexual fitness is determined by providing a subject taking the composition with a sexual function questionnaire. For women, the questionnaire follows the Index of Female Sexual Function (IFSF) . This is a 9-item, self-administered questionnaire. (See Urology 53: 481-486, 1999.) The questionnaire is directed at the level of discomfort during intercourse, the degree of vaginal dryness, the number of attempts at sexual intercourse, the rate and level of sexual desire, the level of satisfaction with a woman' s sex life and relationship, the degree of clitoral sensation during sexual stimulation and the quality of orgasm. In general, the administration of a composition of this invention results in improved sexual fitness as measured by one or more of the factors in the IFSF, e.g., increased clitoral sensation and improved sexual desire.
For men, the improvement in sexual fitness is determined by administering the International Index of Erectile Function (IIEF) , a 15-question, validated, multidimensional, self- administered questionnaire. (See Urology : 49, 822-830.) The questionnaire is directed at determining the ability to obtain an erection, the hardness of an erection, ability to penetrate a partner and maintain the erection, satisfaction level of intercourse, ability to ejaculate and experience orgasm, level of sexual desire, level of satisfaction with sex life and sexual relationship with a partner. In general, the administration of a composition of this invention over time in accordance with the method of the invention results in improved sexual fitness as measured by one or more of the factors in the IIEF, e.g., improved ability to achieve an erection, an erection that can be maintained for a period of time that is longer than would occur without the administration of the dietary supplement, improvement in the quality of the orgasm for the subject. In addition, it is found that upon exertion by any significant exercise the subject' s breathing and ability to breathe is improved.
It is believed that the dietary supplement increases the production of nitric oxide (NO) by providing more substrate (L- arginine) for its production and upregulating the activity of nitric oxide synthase (NOS) , the enzyme that cleaves L-arginine to form NO. NO in turn signals the creation of cGMP which triggers an erection in men. The dietary supplement helps improve the body' s production of cGMP. It is believed that female sexual function is accomplished physiologically in a similar manner. For example, cGMP triggers lubrication and engorgement of the clitoral tissue. Thus, the dietary supplement of the invention is useful for improving sexual wellness, in both men and women. The dietary supplement can also be used in a method of medical treatment, such as, for example, the treatment of sexual dysfunction, or for the preparation of a medicament for such treatment.As shown in Example 7, simultaneous usage of Viagra™ (sildenafil citrate)
and a dietary supplement comprising L-arginine, ginseng and ginkgo biloba improves sexual function in patients who did not respond satisfactorily to Viagra™ alone. Viagra™, which is currently prescribed in 25, 50 and 100 mg dosages for erectile dysfunction, exerts its effects by transiently inhibiting PDE5 , a chemical in the body responsible for the degradation of cGMP in the corpus cavernosum (penis cavity) . In essence, Viagra™ decreases the body' s ability to breakdown cGMP for a short time, allowing more of it to accumulate. The resulting higher levels of cGMP increases the ease in achieving and maintaining an erection.
Alprostadil is a smooth muscle relaxant. The binding of alprostadil to its receptors is accompanied by an increase in intracellular cAMP levels. Human cavernous smooth muscle cells respond to alprostadil by releasing intracellular calcium into the surrounding medium. Smooth muscle relaxation is associated with a reduction of the cytoplasmic free calcium concentration. Alprostadil also attenuates pre-synaptic noradrenaline release in the corpus cavernosum, which is essential for the maintenance of a flaccid and non-erect penis.
The dietary supplement, Viagra ™, and alprostadil all work to facilitate smooth muscle relaxation and vascular dilatation. Thus, yet another aspect of this invention is a method for enhancing the response of a male subject to a pharmaceutical composition which facilitates smooth muscle relaxation and vascular dilatation, preferably which increases the levels of cGMP in the corpus cavernosum. The method is useful for subjects which have an unsatisfactory response to the pharmaceutical composition and wish to improve the efficacy of the pharmaceutical composition. The method comprises administering a daily dosage of a dietary supplement comprising, in at least one unit dosage, L-arginine, ginseng, and ginkgo biloba for a number of days sufficient to improve the ability of a male subject to achieve penile erection when the pharmaceutical composition is administered. Preferably the dietary supplement is administered for at least one day, more
preferably at least about one week, and most preferably at least about two weeks . Other compounds which increase the levels of cGMP include, but are not limited to, alprostadil
The invention also provides a method for reducing the pharmaceutically effective dose of a pharmaceutical composition, such as, e.g., a composition comprising sildenafil citrate and/or alprostadil, which facilitates smooth muscle relaxation and vascular dilatation, preferably which increases the levels of cGMP in the corpus cavernosum. The method is useful for subjects who, having experienced undesirable side effects with their current dosage of the pharmaceutical composition, wish to reduce the dosage to avoid the side effects yet maintain a favorable level of efficacy. The method is also useful for subjects who do not have problems with side effects from the current dosage of the pharmaceutical composition but wish to achieve the same level of efficacy with a reduced dosage for reasons of cost, preference for natural products, etc. The method comprises administering, to a male subject being treated with a first dosage of the pharmaceutical composition, a daily dosage of a dietary supplement comprising, in at least one unit dosage, L-arginine, ginseng, and ginkgo biloba for a time sufficient to enhance the ■ effects on said cGMP levels mediated by a first dosage of a pharmaceutical composition prescribed for erectile dysfunction; and adjusting said first dosage to a second dosage which exerts the same effects on said cGMP levels of said first dosage prior to commencement of said daily dosage of said dietary supplement .
Another preferred aspect of the invention is a method of ameliorating erectile dysfunction, comprising administering a daily dosage of a dietary supplement comprising L-arginine, ginseng, and ginkgo biloba and administering, when an erection is desired, a pharmaceutical composition, such as, e.g., a composition comprising sildenafil citrate and/or alprostadil, which facilitates smooth muscle relaxation and vascular dilatation, preferably which increases the levels of cGMP in the corpus cavernosum. Typically, the pharmaceutical
composition is administered less than about 6 hours before attempting intercourse, preferably from about 4 hours to about 0.5 hour before sexual activity, and most preferably about 1 hour before sexual activity. Preferred dosages of the pharmaceutical composition are about one fourth of the dosages normally prescribed, preferably about one half of the normal dosages. For example, preferred dosages of sildenafil citrate for this method include, but are not limited to, about 6.25 mg, 12.5 mg, 25 mg, and 50 mg dosages.
In general, the administration of the composition of this invention is carried out on a daily basis for a period of time sufficient to improve sexual fitness . The time and amount administered will vary from subject to subject and will be influenced by the age of the subject, whether male or female. Generally, the younger the subject, the sooner the results will be seen and the smaller the amount needed to see the results. As a subject ages, the composition will have to be administered over a longer period of time and in larger amounts for a subject to experience results. The composition is preferably administered for at least two days. More preferably it is administered for at least about a one week period, even more preferably at least about a two week period, and most preferably for at least about a four week period. By ingesting the composition over an extended period of time making the dietary supplement an addition to the diet on a sustained basis, sexual fitness will be improved generally. In administering the composition to an individual, the composition is administered in either the tablet, capsule or liquid form in accordance with the composition discussed herein before. Typically, a desired daily dosage is achieved by administering an appropriate quantity of unit dosages. Generally the amounts administered on a daily basis will be between about 500 mg - 10000 mg of L-arginine per day, preferably about 2000 to 5000 mg of L-arginine a day. The ginseng is administered at a rate of about 25 mg to about 600 mg per day preferably about 100 to about 400 mg per day. The ginkgo biloba is administered at a
rate of about 8 mg to 300 mg per day, preferably about 50 to about 250 mg per day. Optionally up to 200 percent of the da'ily values of antioxidant vitamins, vitamin B complex and certain minerals, as discussed hereinbefore, are administered along with the dietary supplement combination.
The supplement can be administered weekly or even monthly, but daily administration is preferred, preferably on an empty stomach. The daily dosage can be a single unit dosage or a multiple unit dosage. For example, a daily dosage can be from 1 to 10 capsules or 1 to 4 100 ml beverages daily. Preferably the daily dosage is 6 capsules or 2 100 ml beverages. Preferably the daily • dosage is administered in two unit dosages, preferably upon waking and at bedtime. Some preferred dietary supplements are discussed further in Examples 1-3.
Another aspect of this invention is a method for preparing a composition useful for improving sexual fitness. The process comprises combining L-arginine with a material for increasing nitric acid synthase activity (e.g., ginseng) and optionally (a) a material that promotes vascular circulation (e.g., ginkgo biloba) and (b) additional dietary supplements such as vitamins and minerals. The mixture is formed into unit dosage forms and labeled as being useful for improving sexual fitness .
Still another aspect of this invention is an article of manufacture that is a composition in accordance with this invention in combination with labeling that the composition is to be taken for sexual fitness. The article is simply a container such as a bottle or box containing unit dosage forms (e.g., tablets, capsules) with labeling indicating the rate at which the unit dosage should be consumed, e.g., see Examples 1- 3.
During a study on ArginMax for women, the daily nutritional supplement designed to improve sexual fitness and health, an unexpected finding was made. Namely, it was discovered that ArginMax was able to significantly increase libido in women participating in the study versus those on placebo. Specifically, both the level of sexual desire, and
the frequency of sexual desire were enhanced significantly in the ArginMax group .
Due to the fact that libido is regulated centrally, and involves the CNS, there is an inventive aspect that is both unexpected and novel . Certainly, this is a separate phenomenon from the nitric oxide pathway that ArginMax was originally formulated to enhance sexual health. In the present application ArginMax is used to enhance libido and arousal.
Specifically, ArginMax combines certain ingredients such as l-arginine, ginkgo, and ginseng because of their ability to synergistically enhance nitric-oxide production. Enhancing nitric oxide production (or inhibiting the breakdown of biochemical products for which nitric oxide triggers the production of) in the genitalia is known to enhance sexual functioning. In women, this would mean enhanced engorgement and lubrication. However, this functional mechanism is separate from that which regulates libido and arousal, a phenomenon of the central nervous system (CNS) perhaps modulated by sex hormones and specific receptors. It is apparent from our recent studies that ArginMax demonstrates significant ability to enhance libido and arousal in women in addition to enhancing sexual functioning via the nitric oxide cycle .
Given that other major reproductive functions, such as lactation and ovulation, both involve central feed back loop via the CNS, the present ArginMax formulation and the individual components contained in ArginMax may play an important role in the regulation and the optimization of CNS regulated libido. ArginMax for female sexual fitness is a nutritional supplement that incorporates a standardized combination of L-arginine, Korean ginseng (Panax ginseng- 30% ginsenosides) , Ginkgo biloba (24% flavone glycosides, 6% terpene lactones) , and damiana leaf (Turnera aphrodisiaca) , along with vitamins, A, C, E, B6, B12, biotin, folate, niacin, pantothenic acid, riboflavin, thiamin, and minerals, calcium, iron and zinc .
These and further and other objects and features of the invention are apparent in the disclosure, which includes the above and ongoing written specification and the claims .
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The compositions and methods of the invention provide a dietary supplement useful for maintaining a state of wellness in an animal, preferably a laboratory animal or domesticated animal, even more preferably a human, whether male or female.
The composition and method of the invention are particularly useful for improving sexual fitness in both males and females. The composition and method are particularly useful for people who want to remain sexually active as they grow older.
The composition of the invention comprises two, and preferably three, components: (a) a metabolic precursor to nitric oxide, (b) a material for increasing nitric oxide synthase activity, and optionally (c) a material to promote vascular circulation, particularly microvascular circulation. Preferably, the composition is a dietary supplement that is delivered over time to achieve the desired results.
A preferred dietary supplement of the invention comprises a combination of arginine, ginseng, and optionally ginkgo biloba, which is useful for improving blood flow and circulation. Improved blood flow is important for maintaining good sexual health. The compositions and methods of the invention improve sexual wellness without any undesirable side effects such as headache, nausea, gastric upset, chest pain, dizziness, vision disturbance, or change in blood pressure.
The Composition
The main component of the composition of this invention is a metabolic precursor to nitric oxide (NO), such as, for example, organic nitrates and nitrites and other compounds that are capable of conversion to nitric oxide . Many of such precursors are also called nitrovasodilators . Examples of
organic nitrates include isoamyl nitrate, nitroglycerin, isosorbide dinitrate, erythrityl tetranitrate and pentaerythritol . Preferably, the precursor to NO is arginine. Arginine is an essential amino acid having the chemical name 2- amino-5-guanidinovaleric acid. It is preferably used in the physiologically active form which is designated as the " L" form. The compound is readily available from various sources in the commercial market place such as from Sigma Chemical Company or Aldrich Chemical Company in a pharmaceutical grade. It generally is available as a powder that generally is associated with two moles of water and forms monoclinic plates. Preferably the L-arginine ' in the composition is free of other amino acids, peptides and proteins that would interfere with the uptake of L-arginine into the animal' s system.
The second component present in the composition is a material that increases nitric oxide synthase (NOS) activity. The increase in NOS activity may result from the increase in the quantity of NOS in the system or from an improvement in the level of activity of NOS or by some other manner. A preferred material is ginseng. Ginseng is material extracted from the root of a plant that is a member of the ginseng family (Araliaceae) , genus Panax . Ginseng plants grow in Asia and North America. P. ginseng grows in Northern China (Chinese ginseng) and Korea (Korean ginseng) . The material extracted, from the root is referred to as white ginseng or red ginseng. The former is dried P. ginseng root, while the latter is P. ginseng root steamed in caramel. American ginseng (P. quinquefolium) generally grows in the northern U.S. and Canada. Other relatives include Japanese ginseng (P. iaponicum) , San- Chi ginseng (P. notoginseng) , Himalayan ginseng (P. pseudoginseng , ssp. himalaicus var argustifolius) , and Siberian ginseng (Eleutherococcus senticosus) .
The ginseng component in the composition is usually standardized ginseng obtained from plants originating from one or more geographical areas, and comprises, in total, about 1% to about 50% ginsenosides, preferably about 10% to about 35%
ginsenosides, more preferably about 15% to about 20% ginsenosides, most preferably about 17.5% ginsenosides. Preferably the ginseng component comprises American ginseng and Korean ginseng. The American ginseng comprises about 1% to about 50% ginsenosides, preferably about 1% to about 10% ginsenosides, more preferably about 5% ginsenosides. The Korean ginseng comprises about 1% to about 50% ginsenosides, preferably about 10% to about 40% ginsenosides, more preferably about 30% ginsenosides. The ginseng component in a liquid or tonic is usually one or more extracts of ginseng from various geographical areas having a ratio of herb to solvent when extracted of about 1:2 to about 1:10, preferably about 1:5.
The various types of ginseng are available on the commercial market and are available from various sources, such as, for example, East Earth Herb and Natural Sourcing Solutions, Inc. The types and relative abundance of the chemical constituents of ginseng depend on the species, the part of the plant, the place of origin, the method of cultivation, and the technique of extraction used to obtain the ginseng. Different types of ginseng may have slightly different constituent profiles, but the type of ginseng used in this composition will be the material extracted from Panax ginseng or Panax quinquefolius . Preferably a mixture of American ginseng and Korean ginseng is employed.
The composition of the ginseng extracted from the roots of the various plants is quite similar among the different species used. Generally the ginseng will contain typical ginsenosides. A further discussion of the constituents of the various types of ginseng may be found in the American Chemical Society publication entitled "Folk Medicine: The Art and the Science," edited by Richard P. Steiner, University of Utah (1986) .
Preferably, the composition of this invention also comprises a material that promotes vascular circulation in the person receiving the composition. This material may be a pharmaceutical or a dietary supplement or herb. Some materials that promote vascular circulation are known as vasodilators,
e.g., hydralazine, minoxidil, sodium nitroprusside, dia oxide, phentolamine mesylate, phentolamine hydrochloride, phenoxybenzamine, yohimbine, nitroglycerine, thymoxamine, imipramine, isoxsuprine, naftidrofuryl, tolazoline, papaverine, and calcium channel blockers that act as vasodilators, such as nifedipine, nicardipine, nimodipine, verapamil and diltiazem. A particularly preferred material that promotes vascular circulation is Ginkgo biloba. Ginkgo biloba is extracted from the leaves of the ginkgo biloba tree. The leaves are harvested ■ in late summer when the leaves have the highest level of active compounds. The extract is semipurified to remove undesirable compounds which do not contribute to the desired health benefits . The material can be highly concentrated and standardized to a known and consistent level of the active principals known as ginkgolides. Ginkgo biloba is readily available from the various sources throughout the herbal medicine industry, such as, for example, East Earth Herb and Natural Sourcing Solutions, Inc.
The ginkgo component in the composition as a solid, e.g., a tablet, capsule, or powder, is usually standardized ginkgo and comprises about 1% to about 50% flavone glycosides, preferably about 15% to about 30% flavone glycosides, more preferably about 24% flavone glycosides, and about 1% to about 20% terpene lactones, preferably about 5% to about 10% terpene lactones, more preferably about 6% terpene lactones. The ginkgo component in a liquid or tonic is usually an extract having a ratio of herb to solvent when extracted of about 1:2 to about 1:5, preferably about 1:2.
A dietary supplement composition comprising the combination of L-arginine, ginseng, and ginkgo biloba is administered to a subject orally as a capsule, tablet, powder or as an aqueous composition. If administered as a capsule, tablet, or powder, an amount of each of the three constituents is mixed in accordance with standard pharmaceutical practice to form a unit dosage that can be swallowed by taking water with the unit dosage. (See, for example, "Remington, The Science
and Practice of Pharmacy," Nineteenth Edition, Mack Publishing co . for a discussion of the preparation of tablets and capsules/chapters 91-93) . In general, the size of the tablet or capsule will be less than about a gram to maximize the ease of swallowing. In addition to the three major components of the composition of this invention, a dietary supplement also may contain antioxidant vitamins, vitamin-B-complex, and certain minerals. These additional constituents may be present in an amount up to about 100% of the daily values for each constituent for a male or female. By "daily values" is meant the Reference Daily Intake (RDI) as defined in 21 CFR §101.9 (c) (8) (iv) . Antioxidant vitamins include vitamins A (preferably as palmitate) , C (preferably as ascorbic acid) and E (preferably as dl tocopherol acetate) . Vitamin-B complex includes thiamin (preferably as the mononitrate) , riboflavin, niacin (preferably is niacinamide) , vitamin B-6 (preferably as pyroxidine HC1) , folate (preferable as folic acid) , vitamin B- 12 (preferably as cyanocobalamin) , biotin, and pantothenic acid (preferably as calcium pantothenate) . Minerals include zinc (preferably as zinc gluconate) , calcium (preferably as calcium carbonate, iron (as iron gluconate) , and selenium (preferably as sodium selenate) .
Where a dietary supplement of this invention is administered in tablet, capsule, or powder form, the daily dosage can be administered in single or multiple unit dosages, preferably 1 to 10 unit dosages, more preferably 4-6 unit dosages. The constituents are combined to form a unit dosage in accordance with the amounts set forth in Table A, in which the broad, preferred, and more preferred range is are set forth as milligrams (mg) or % Daily Values.
The following outlines the materials, methods and results of the study that supports the unexpected findings discussed above. The results provide evidence of increases in libido as reported in the following findings :
Materials:
In a preferred embodiment, the dietary supplement for wellness includes, but is not limited to, in a unit dosage a combination of (a) L-arginine, (b) ginseng, (c) ginkgo biloba, and (d) damiana. Preferably, the unit dosage is in a capsule or a tablet form or as an aqueous composition.
The dietary supplement preferably includes about 50 mg to about 5000 mg L-arginine; about 5 mg to about 600 mg ginseng; about 5 mg to about 300 mg ginkgo biloba, and about 0 mg to about 300 mg damiana. The preferred composition may also include in a unit dosage an amount of antioxidant vitamins, vitamin B complex, and minerals sufficient to provide up to about 100% to about 200% of the percent daily values of the antioxidant vitamins, vitamin B complex, and minerals upon administering an appropriate quantity of the unit dosages to achieve a desired daily dosage. The daily dosage may be in an amount of, but is not limited to, about 50 ml to about 600 ml. of an aqueous composition and may be administered as a beverage .
A preferred dietary supplement may be in the form of an aqueous drink of about 100 ml comprising (a) about 1500 mg L- arginine; (b) about 100 mg Korean ginseng; (c) about 100 mg ginkgo biloba; (d) about 50 mg damiana; (e) about 100% of the daily value of each of vitamins A, C, and E; (f) about 100% of the daily value of each of thiamin, riboflavin, niacin, vitamin B-6, folate, vitamin B-12, biotin, pantothenic acid; and (g) about 50% of the daily value of iron, calcium, and zinc. Additionally, the desired daily dosage of the dietary supplement may include administering up to 200% of the percent daily values of antioxidant vitamins and vitamin B complex, and up to 100% of the percent daily value of minerals.
The composition may be administered daily to a subject for a time sufficient for sexually arousing the subject more easily than without administration of the combination. The daily dosage is administered to the subject for a time sufficient to improve the quality of orgasm for the subject. The dietary supplement may be administered to the subject for a period of
time sufficient to improve the frequency of desire to engage in sexual activity.
Methods :
All participants were enrolled based on their expressed interest in improving their current sexual function. Twelve had been previously treated for sexual dysfunction. Ninety- three (93) study participants, ages 22-73, successfully followed and completed the study protocol . The survey instrument was the Female Sexual Function Index (FSFI) , a validated questionnaire with multidimensional scales for assessment of sexual function used in the evaluation of Viagra (sildenafil citrate) in women (Kaplan et al . , 1999). Medical histories, including self-assessment of menopausal status, and FSFI scores were collected at 0 and 4 weeks. Upon enrollment, subjects were randomly assigned ArginMax or placebo in a double-blind fashion.
Of the 93 subjects who completed the test protocol, forty- six (46) subjects were on ArginMax and forty-seven (47) were on placebo. The age distributions were similar, with the ArginMax group ranging from 24 to 73 (mean 42.2) , and the placebo group ranging from 22 to 68 (mean 41.3) . Sel -assessment of menopausal status resulted in 58 women being categorized as premenopausal (PRE) , 16 as perimenopausal (PERI) , and 19 as postmenopausal (POST) .
Results:
Summaries of FSFI data in Table 1 demonstrate significant improvements in many parameters among the ArginMax (Active) groups as compared to the placebo groups, categorized as PRE, PERI or POST in menopausal status .
The PERI women on ArginMax reported the most improvements, as a group, including decreased dryness (Q2, 64% of group; p=0.07), increased frequency of sex (Q3 , 91%, p<0.01), increased frequency of sexual desire (Q4, 73%), improved satisfaction with sexual relationship (Q7, 73%) , and increased
clitoral sensation (Q9 , 73%) . These same parameters increased only 20 to 40% in the PERI group on placebo.
PRE women on ArginMax improved primarily in desire (Q4 and 5, 58% vs 38-47% on placebo; p<0.05) and satisfaction with overall sex life (Q6, 67% vs. 35% on placebo; p<0.01). POST women, as a group, increased mainly in satisfaction with sexual relationship (Q7, 64% vs. 38% on placebo), and in level of sexual desire (Q5, 45% vs. 13% on placebo, p=0.08) . These differences demonstrate a shift in the pattern of attributes that show improvement among the different menopausal status groups .
Overall (in Table 2) , the largest improvements across all groups on ArginMax occurred in level of sexual desire (Q5, 64% vs. 43% on placebo , p<0.01), and in frequency of intercourse (Q3, 64% vs. 28% on placebo, p<0.001).
Combining PRE and PERI women on ArginMax resulted in 71% increase in sexual desire and 68% increase in satisfaction with overall sex life (vs. 49% and 36%, respectively, on placebo for Q5 and Q6; p<0.01) .
Tables 1 and 2 demonstrate the significant differences in mean score increases for these parameters, the ArginMax group showing almost a full point increase, on average, more than the placebo group, in both sexual desire and satisfaction with overall sex life.
Since POST women increased mainly in satisfaction with sexual relationship, more so than in sex life satisf ction, combining groups dilutes the overall increase in percent improved for any one attribute. Additionally, significant increases (p<0.05) were noted in the combined ArginMax groups for degree of lubrication (Q2, decreased dryness) , frequency of sexual intercourse (Q3) and sexual desire (Q4) , satisfaction with sexual relationship (Q7) , frequency of orgasm (Q8) and degree of clitoral sensation (Q9) relative to the placebo group (see Table 2) .
No visual disturbance, blood pressure alterations, dizziness, hypersensitivity or other significant side effects
were noted in either group. Four participants noted minor gastric disturbances, two noticed heavier bleeding during their periods and one had increased incidence of headaches .
EXAMPLES
Example 1 - Dietary Supplement in Gel Cap Form
The dietary supplement is provided in a 6 gel cap serving to be taken daily, preferably by a human male, for at least 2-3 weeks, preferably on an empty stomach, and comprises the following components per serving:
Vitamin A 5000IU
Vitamin C 60 mg
Vitamin E 30 IU
Thiamin 1.5 mg
Riboflavin 1.7 mg
Niacin 20 mg
Vitamin B-6 2 mg
Folate 400 meg
Vitamin B-12 6 meg
Biotin 300 meg
Pantothenic acid 10 mg
Zinc 15 mg
Selenium 70 meg
L-arginine 3000 mg
American Ginseng - standardized 100 mg
(5% ginsenosides) Korean Ginseng - standardized 100 mg
(30% ginsenosides) Ginkgo Biloba - standardized 50 mg
(24% flavone glycosides, 6% terpene lactones)
Other ingredients: Rice Flour Powder, Magnesium Stearate, Silica Example 2 - Dietary Supplement in Tonic Form
The dietary supplement is provided in two 100 ml servings to be taken daily, preferably by a human male, for at least 2-3 weeks, preferably on an empty stomach, and comprises the following components per serving:
Vitamin A 5000 IU
Vitamin C 60 mg
Vitamin E 30 IU
Thiamin 1.5 mg
Riboflavin 1.7 mg
Niacin 20 mg
Vitamin B-6 2 mg
Folate 400 meg
Vitamin B-12 6 meg
Biotin 300 meg
Pantothenic acid 10 mg
Zinc 7.5 mg
Selenium 70 meg
L-arginine 1500 mg
American Ginseng - root (1:5) 100 mg
Korean Ginseng - root (1:5) 100 mg
Ginkgo Biloba - fresh leaf (1:2) 100 mg
Other ingredients: Filtered Water, High Fructose Corn Syrup, Strawberry Concentrate, Citric Acid, Natural Flavors Example 3 - Dietary Supplement in Gel Cap Form
The dietary supplement is provided in a 6 gel cap serving to be taken daily, preferably by a human female, for at least 2-3 weeks, preferably on an empty stomach, and comprises the following components per serving:
Vitamin A 5000IU
Vitamin C 60 mg
Vitamin E 30 IU
Thiamin 1.5 mg Riboflavin 1.7 mg
Niacin 20 mg
Vitamin B-6 2 mg
Folate 400 meg
Vitamin B-12 6 meg
Biotin 300 meg
Pantothenic acid 10 mg
Calcium 500 mg
Iron 9 mg
Zinc 7.5 mg
L-arginine 2500 mg
Korean Ginseng - standardized 100 mg
(30% ginsenosides) Ginkgo Biloba - standardized 50 mg
(24% flavone glycosides, 6% terpene lactones) Damiana leaves 50 mg
(Turnera Aphrodisiaca)
Other ingredients: Rice Flour Powder, Magnesium Stearate, Silica
Example 4 - Regular administration of L-arginine to maintain a state of wellness thereby reducing the likelihood of developing a headache
A healthy man takes 3,000 mg L-arginine as a separate dietary supplement daily on an empty stomach for a minimum of 2-3 weeks.
Example 5 - Regular administration of L-arginine in combination with ginseng and ginkgo biloba to maintain a state of wellness
18 healthy men, age 29 to 44, were instructed to take two 100 ml servings of the dietary supplement described in Example 2 daily on an empty stomach for eight weeks . Survey data was collected before and after the men begin taking the dietary supplement. The volunteers noted a 29 to 33% increase in quality of orgasm, sexual confidence and sexual stamina. Penile hardness ratings and sexual enjoyment ratings increased
by 13%. Ease of breathing after exertion also increased by 29%. Frequency of headaches decreased.
Example 6 - Administration of L-arginine in combination with ginseng and ginkgo biloba in men with erectile dysfunction
Male subjects with mild to moderate erectile dysfunction were instructed on the use and regimen of the dietary supplement of Example 1 and were requested to fill out a baseline SFQ survey. Subjects started a twice-per-day regimen of the dietary supplement, once in the morning upon waking and once in the evening at bedtime. A 4 -week supply of the dietary supplement was provided. After completing the 4 -week regimen, patients were instructed to complete a 4 -week SFQ survey and return to the test center for follow-up evaluation and examination.
The SFQ was used as the primary test instrument . The SFQ is a self-administered questionnaire beginning with the validated IIEF (International Index of Erectile Function used with permission) test instrument and including other validated test instruments designed to measure changes in erectile function, sexual function, and quality of life. (Rosen et al., Urology, June 1997, 49 (6) : 822-830 ; Derogatis LR, J Sex Marital Ther, 1997, 23 (4) : 291-304 ; Conte HR, Arch Sex Behav, December 1983, 12 (6) : 555-576 ; Jenkinson et al . , BMJ, May 29, 1993, 306 (6890) :1437-1440; Garrarr et al . , BMJ, May 29, 1993, 306(6890) : 1440-1444) In addition, the SFQ included questions regarding subject' s activities and condition during the trial period.
Subject Group Profile at Baseline: Total # of subjects 25 Age range 40-77
# hypertensive 19
# diabetes mellitus 4
Patient responses to SFQ survey questions at 4 weeks were compared to SFQ responses at baseline. A comparison analysis was performed for those subjects whose degree of erectile dysfunction were mild to moderate as characterized by a minimal baseline score of 2. For each SFQ variable, a comparison was made of those subjects who initially had a baseline score of at least 2 to their 4 week score on the same variable. The results were then pooled, summarized, and evaluated to reflect the percentage of subjects with improvement in each of the SFQ question variables. 88.9% of subjects showed improvement in the ability to maintain erection during intercourse. 75.0% of subjects showed improvement in satisfaction with overall sex life. 20.0% of subjects showed improvement in number of orgasms. 12.5% of subjects showed improvement in the number of times attempted intercourse.
There were no significant changes in blood pressure or other significant side effects as noted by net % of patients reporting increase or decrease as follows:
Headaches : -4 8%
Nausea: -4.8%
Stomach upset : -14.3%
Chest pain: 0%
Dizziness : 0%
Vision disturbance: 0%
Example 7 - Administration of L-arginine in combination with ginseng and ginkgo biloba in patients that had not responded satisfactorily to Viagra™
Six patients which had not responded satisfactorily to Viagra™ (sildenafil citrate) were asked to use the dietary supplement of Example 1 for 4 weeks on a daily basis and to
try Viagra™ again as they felt the need. Typically patients used Viagra™ about 1 hour prior to engaging in sexual activity. Patients were using either 50 or 100 mg dosages of Viagra™ . 4 out of 6 showed dramatic improvement based on an increase in several key IIEF variables, such as erection frequency, erection firmness, penetration ability, maintenance frequency, and maintenance ability.
Example 8 - Female clinical study regarding sexual fitness
A double-blind, placebo-controlled study was carried out examining the role of dietary supplementation in female sexual function. A composition of Example 3 was given to thirty-nine
(39) participants, ages 22-61 years. All individuals were experiencing some degree of sexual dysfunction. Evaluations were conducted using the Female Sexual Function Index (FSFI) , a validated instrument used for the evaluation of sildenafil
(Viagra) in women. Of the l39 participants, sixteen (16) received the composition and twenty-three (23) received placebo. At week four, 62.5% of women in the active group experienced improvement in clitoral sensation during sexual stimulation compared to 39.1% in the placebo group. In the active group, 68.8% experienced improvement in their level of sexual desire compared to 43.5% in the placebo group p=0.06. No headache, nausea, vomiting, stomach upset, visual disturbance, hypotension, dizziness or other complaints were noted in either group.
All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference .
The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims .
While the invention has been described with reference to specific embodiments, modifications and variations of the invention may be constructed without departing from the scope of the invention, which is defined in the following claims.
TABLE 1- Results from the Female Sexual Function Index fFSFTK Active vs. Placebo
Active, PRE: 24 women
FSFI Question 1 * 2b 3e 4d 5° 6f 7* 8h 9' mean score, start 3.8 3.5 2.9 2.2 1.9 2.0 2.5 3.0 2.9 mean score, 4 wks 4.3 4.1 3.7 3.2 3.2 3.2 3.4 3.8 3.5 % improved 33% 50% 58% 58% 58% 67% 42% 50% 33%
Placebo, PRE: 34 women
FSFI Question 1 ' 2b 3C 4d 5e 6f 7« 8h 9' mean score, start 3.7 3.1 3.3 2.0 1.8 2.3 2.6 2.7 2.7 mean score, 4 wks 3.6 3.0 3.4 2.3 2.2 2.6 3.1 3.0 3.0 % improved 24% 29% 26% 38% 47% 35% 35% 29% 38% p values 0.28 0.13 0.004 0.04 0.01 0.004 0.15 0.13 0.21 Active, PERI: 11 women
FSFI Question 1 * 2b 3C 4d 5e 6f 7* 8h 9' mean score, start 3.6 2.8 3.4 2.1 1.6 2.0 2.5 2.5 2.6 mean score, 4 wks 4.2 3.7 4.6 2.9 2.3 3.1 3.6 3.4 3.6 % improved 36% 64% 91% 73% 64% 64% 73% 55% 73%
Placebo, PERI: 5 women
FSFI Question 1 * 2b 3C 4" 5β 6f 7* 8" 91 mean score, start 4.2 3.2 3.2 1.4 1.4 2.0 2.4 2.4 2.0 mean score, 4 wks 4.6 3.2 3.0 1.6 2.0 2.6 2.6 2.2 2.4 % improved 20% 20% 20% 40% 60% 40% 40% 20% 40% p values 0.31 0.07 0.004 0.11 0.43 0.20 0.11 0.12 0.11 Active, POST: 11 women
FSFI Question 1 * 2" 3C 4d 5β 6f 7« 8" 9' mean score, start 2.6 1.8 1.9 1.7 .5 2.0 2.2 2.2 2.2 mean score, 4 wks 2.9 2.6 2.5 1.9 1.9 2.6 3.2 2.7 2.6 % improved 18% 27% 45% 36% 45% 45% 64% 36% 36%
Placebo, POST: 8 women
FSFI Question 1 ' 2b 3C 4d 5e 6f 7* 8h 91 mean score, start 2.6 1.8 3.0 2.0 1.9 2.0 2.3 1.5 1.9 mean score, 4 wks 2.6 2.0 3.1 2.1 1.9 2.1 2.4 2.1 1.9 % improved 13% 13% 38% 25% 13% 50% 38% 50% 13% p values 0.41 0.26 0.38 0.32 0.08 0.57 0.14 0.72 0.15
'1. Over the past 4 weeks how often did you experience discomfort during sexual intercourse?
(l=Almost always, 2-Most times, 3-Sometimes, 4-Afew times, 5 -Almost never). *2. Over the past 4 weeks how often did you experience dryness during sexual intercourse?
(1-Almost always, 2-Most times, 3-Sometimes, 4-A few times, 5 -Almost never). *3. Over the past 4 weeks how often did you attempt sexual Intercourse?
(1-0, 2-1-2, 3-3-4, 4-5-6, 5=7-10, 6-11+). '4. Over the past 4 weeks how often have you felt sexual desire? ,
(I-AImost never, 2=A few times, 3-Sometimes, 4- ost times, 5 -Almost always). *5. Over the past 4 weeks how would you rate your level of sexual desire?
(1-Very low, 2-Low, 3-Moderate, 4-Hιgh, 5- Very high). %. Over the past 4 weeks how satisfied have you been with your overall sex life?
(1 -Very dissatisfied, 3=About equally satisfied and dissatisfied, 5-Very satisfied). •7. Over the past 4 weeks how satisfied have you been with your sexual relationship with your partner?
(1-Very dissatisfied, 3-About equally satisfied and dissatisfied, 5-Very satisfied), k8. Over the past 4 weeks, when you had sexual stimulation or intercourse, how often did you have the feeling of orgasm?
(l=Almost never, 2=A few times, 3=Som-times, 4=Most times, 5 -Almost always). "9. Over the past 4 weeks, when you had sexual stimulation or intercourse, how would you rate your degree of clitoral sensation? (1-Very low, 2=Low, 3-Moderatc, 4-High, 5-Very high).
TABLE 2- Summary results from the Female Sexual Function Index (FSFIY Active vs. Placebo
Active, total: 46 women
FSFI Question 1 * 2" 3C 4d 5° 6f 7« 8h 9' mean score, start 3.5 2.9 2.8 2.0 1.7 2.0 2.4 2.7 2.7 mean score, 4 wks 3.9 3.7 3.6 2.8 2.7 3.0 3.4 3.4 3.3 % improved 28% 46% 64% 58% 64% 62% 58% 47% 53%
Placebo, total: 47 women
FSFI Question 1 « 2 b 3C 4d 5« 6f 7« 8" 9' mean score, start 3.6 2.9 3.2 1.9 1.8 2.2 2.5 2.5 2.5 mean score, 4 wks 3.6 2.9 3.3 2.2 2.1 2.5 2.9 2.7 2.7 % improved 21% 26% 28% 36% 43% 38% 36% 32% 34% p values 0.16 0.02 <0.001 0.03 0.008 0.009 0.02 0.06 0.04 Active, PRE+PERI only: 35 women
FSFI Question 1 ' 2 3° 4d 5e 6f 7* 8" 9' mean score, start 2.9 2.5 2.3 1.6 1.4 1.5 1.9 2.1 2.1 mean score, 4 wks 3.2 3.0 3.0 2.4 2.2 2.4 2.7 2.8 2.7 % improved 31% 51% 71% 65% 71% 68% 56% 50% 59%
Placebo, PRE+PERI only: 39 women
FSFI Question 1 » 2 b 3° 4d 5e 6f 7« 8" 9* mean score, start 3.1 2.6 2.7 1.6 1.5 1.9 2.1 2.2 2.2 mean score, 4 wks 3.1 2.5 2.8 1.8 1.8 2.2 2.5 2.4 2.4 % improved 23% 28% 26% 38% 49% 36% 36% 28% 38% p values 0.15 0.02 <0.001 0.03 0.01 0.003 0.04 0.02 0.06
*1. Over the past 4 weeks how often did you experience discomfort during sexual intercourse?
(l=Almost always, 2=Most times, 3=Sometimes, 4=A few times, 5 =Almost never). b2. Over the past 4 weeks how often did you experience dryness during sexual intercourse? (1= Almost always, 2= ost times, 3=Sometimes, 4=A few times, 5 = Almost never). c3. Over the past 4 weeks how often did you attempt sexual intercourse?
(1=0, 2=1-2, 3=3-4, 4=5-6, 5=7-10, 6=11+). d4. Over the past 4 weeks how often have you felt sexual desire?
(l=Almost never, 2=A few times, 3=Sometimes, 4=Most times, 5 =Almost always). •5. Over the past 4 weeks how would you rate your level of sexual desire?
(l=Very low, 2=Low, 3=Moderate, 4=High, 5=Very high). f6. Over the past 4 weeks how satisfied have you been with your overall sex life?
(l=Very dissatisfied, 3=About equally satisfied and dissatisfied, 5=Very satisfied). »7. Over the past 4 weeks how satisfied have you been with your sexual relationship with your partner?
(l=Very dissatisfied, 3=About equally satisfied and dissatisfied, 5= Very satisfied). h8. Over the past 4 weeks, when you had sexual stimulation or intercourse, how often did you have the feeling of orgasm?
(l=Almost never, 2=A few times, 3=Sometimes, 4=Most times, 5 =Almost always). *9. Over the past 4 weeks, when you had sexual stimulation or intercourse, how would you rate your degree of clitoral sensation? (l=Very low, 2=Low, 3= oderate, 4=High, 5=Very high).
Claims (25)
1. A dietary supplement for wellness, comprising in a unit dosage a combination of (a) L-arginine, (b) ginseng, (c) ginkgo biloba, and (d) damiana.
2. The dietary supplement of claim 1, wherein said unit dosage is a capsule or a tablet .
3. The dietary supplement of claim 2 comprising
(a) about 50 mg to about 4500 mg L-arginine,
(b) about 0 mg to about 500 mg ginseng,
(c) about 0 mg to about 200 mg ginkgo biloba, and
(d) about 0 mg to about 300 mg damiana.
4. The dietary supplement of claim 3 , further comprising in a unit dosage an amount of antioxidant vitamins, vitamin B complex, and minerals sufficient to provide up to 100% of the percent daily values of the antioxidant vitamins, vitamin B complex, and minerals upon administering an appropriate quantity of the unit dosages to achieve a desired daily dosage .
5. The dietary supplement of claim 4, comprising
(a) about 300 mg to about 2500 mg L-arginine,
(b) about 20 mg to about 200 mg ginseng,
(c) about 20 mg to about 70 mg ginkgo biloba, and
(d) about 5 mg to about 100 mg damiana.
6. The dietary supplement of claim 1, wherein the unit dosage is an aqueous composition.
7. The dietary supplement of claim 6, comprising
(a) about 500 mg to about 5000 mg L-arginine,
(b) about 25 mg to about 600 mg ginseng,
(c) about 12.5 mg to about 300 mg ginkgo biloba, and
(d) about 5 mg to about 100 mg damiana.
8. The dietary supplement of claim 7, further comprising in a unit dosage an amount of antioxidant vitamins, vitamin B complex, and minerals sufficient to provide up to 100% of the percent daily values of the antioxidant vitamins, vitamin B complex, and minerals upon administering an appropriate quantity of the unit dosages to achieve a desired daily dosage .
9. The dietary supplement of claim 8, wherein the daily dosage is in an amount of about 50 -ml to about 250 ml.
10. The dietary supplement of claim 8, comprising
(a) about 750 mg to about 3000 mg L-arginine,
(b) about 100 mg to about 400 mg ginseng,
(c) about 50 mg to about 250 mg ginkgo biloba, and
(d) about 10 mg to about 80 mg damiana.
11. The dietary supplement of claim 10, wherein the dosage is an aqueous drink of about 100 ml comprising
(a) about 1500 mg L-arginine,
(b) about 100 mg Korean ginseng, (c) about 100 mg ginkgo biloba,
(d) about 50 mg damiana,
(e) about 100% of the daily value of each of vitamins A, C, and E,
(f) about 100% of the daily value of each of thiamin, riboflavin, niacin, vitamin B-S, folate, vitamin B-12, biotin, pantothenic acid, and
(g) about 50% of the daily value of iron, calcium, and zinc.
12. The dietary supplement of claim 1, wherein said supplement is for women's wellness.
13. A method for enhancing libido, level of sexual desire, and/or frequency of sexual desire in a human subject, which method comprises administering a sufficient quantity of unit dosages of a dietary supplement to achieve a desired daily dosage, the unit dosage comprising (a) L-arginine, (b) Ginseng, (c) Ginkgo biloba, and (d) damiana.
14. The method of claim 13, wherein the administering a unit dosage comprises administering the dietary supplement as a capsule or a tablet .
15. The method of claim 13, wherein the administering a unit dosage comprises administering
(a) about 500 mg to about 3000 mg L-arginine,
(b) about 0 mg to about 300 mg ginseng,
(c) about 0 mg to about 150 mg ginkgo biloba, and (d) about 0 mg to about 150 mg damiana.
16. The method of claim 15, wherein the administering the desired daily dosage of the dietary supplement comprises administering up to 100% of the percent daily values of antioxidant vitamins, vitamin B complex, and minerals.
17. The method of claim 16, wherein the administering the unit dosage comprises administering
(a) about 2000 mg to about 3000 mg L-arginine,
(b) about 50 mg to about 150 mg ginseng,
(c) about 20 mg to about 70 mg ginkgo biloba, and
(d) about 10 mg to about 100 mg damiana.
18. The method of claim 13, wherein the administering the dietary supplement comprises administering as an aqueous composition.
19. The method of claim 18, wherein the administering the unit dosage comprises administering
(a) about 500 mg to about 5000 mg L-arginine,
(b) about 25 mg to about 600 mg ginseng,
(c) about 12.5 mg to about 300 mg ginkgo biloba, and
(d) about 5 mg to about 300 mg damiana.
20. The method of claim 19, wherein the administering the desired daily dosage of the dietary supplement comprises administering up to 200% of the percent daily values of antioxidant vitamins and vitamin B complex, and up to 100% of the percent daily value of minerals.
21. The method of claim 20, wherein the administering the unit dosage comprises delivering as a beverage of about 50 ml to 600 ml.
22. The method of claim 13, wherein the administering comprises administering a combination daily to a subject for a time sufficient for sexually arousing the subject more easily than without administration of the combination.
23. The method of claim 13, wherein the administering comprises administering a combination to the subject for a time sufficient for improving the quality of orgasm for the subject .
24. The method of claim 13, wherein the dietary supplement is administered to the subject for a period of time sufficient to improve the frequency of desire to engage in sexual activity.
25. The method of claim 13, wherein the administering to the human subject comprises administering to a female subject.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29529701P | 2001-06-01 | 2001-06-01 | |
| US60/295,297 | 2001-06-01 | ||
| US10/157,185 US20050196470A9 (en) | 1998-04-03 | 2002-05-30 | Method and composition for enhancing sexual desire |
| US10/157,185 | 2002-05-30 | ||
| PCT/US2002/017036 WO2002102163A1 (en) | 2001-06-01 | 2002-06-03 | Method and composition for enhancing sexual desire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002310212A1 true AU2002310212A1 (en) | 2003-05-15 |
| AU2002310212B2 AU2002310212B2 (en) | 2006-09-14 |
Family
ID=26853886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002310212A Expired - Fee Related AU2002310212B2 (en) | 2001-06-01 | 2002-06-03 | Method and composition for enhancing sexual desire |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050196470A9 (en) |
| EP (1) | EP1406496A4 (en) |
| JP (1) | JP2004536822A (en) |
| KR (1) | KR20040014540A (en) |
| AU (1) | AU2002310212B2 (en) |
| WO (1) | WO2002102163A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2491938B1 (en) | 2004-12-24 | 2017-08-09 | Dolphst Pty Ltd | Formulations for well-being |
| FR2882896B1 (en) * | 2005-03-14 | 2007-05-04 | Larena Sa | FOOD COMPOSITION FOR PREVENTING FRAGILITY SYNDROME IN OLDER PEOPLE |
| WO2007143002A2 (en) * | 2006-05-31 | 2007-12-13 | Interhealth Nutraceuticals, Inc. | Nutraceutical treatments for diabetic and non-diabetic wound healing |
| US20100062087A1 (en) * | 2006-06-02 | 2010-03-11 | Interhealth Nutraceuticals, Inc. | Nutraceutical Treatments for Diabetic and Non-Diabetic Wound Healing |
| WO2007143631A2 (en) * | 2006-06-02 | 2007-12-13 | Interhealth Nutraceuticals, Inc. | Nutraceutical treatments for diabetic and non-diabetic wound healing |
| JP2010163425A (en) * | 2008-12-18 | 2010-07-29 | Daiichi Sankyo Healthcare Co Ltd | Medicinal composition containing phosphodiesterase-5 inhibitor and pantethine |
| JP2010163426A (en) * | 2008-12-18 | 2010-07-29 | Daiichi Sankyo Healthcare Co Ltd | Medicinal composition containing phosphodiesterase-5 inhibitor and arginine |
| RU2458537C1 (en) * | 2011-03-14 | 2012-08-20 | Общество С Ограниченной Ответственностью "Парафарм" | Biologically active food additive for prevention of men's erectile dysfunction |
| FR2975007B1 (en) * | 2011-05-12 | 2014-03-07 | Philippe Davioud Lab | COMPOSITION FOR TREATING SEXUALITY DISORDERS |
| ITLI20110007A1 (en) * | 2011-09-10 | 2013-03-11 | Lloyds Internat Credit Llc | AN INNOVATIVE NATURAL COMPOSITION EFFECTIVE FOR THE CARE OF IMPOTENCE |
| US8691295B2 (en) * | 2011-10-26 | 2014-04-08 | John Michael Richards | Dietary supplement for vascular health |
| WO2014089344A2 (en) | 2012-12-05 | 2014-06-12 | Ge Nutrients, Inc. | Use of fenugreek extract to enhance female libido |
| CN103404844A (en) * | 2013-04-26 | 2013-11-27 | 江南大学 | Composition capable of enhancing stability of lycopene and having function of relieving physical fatigue and preparation method thereof |
| KR101751211B1 (en) | 2014-12-17 | 2017-06-28 | 홍상근 | Composition for improving sexual function, Functional food Composition for improving sexual function comprising of the same and Manufacturing method thereof |
| US11541092B2 (en) * | 2020-04-08 | 2023-01-03 | Libby and Co. LLC | Composition for increasing sexual desire or pleasure |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2878124A (en) * | 1956-03-10 | 1959-03-17 | Bayer Ag | Food additives |
| US3015567A (en) * | 1959-03-20 | 1962-01-02 | Du Pont | Process for enriching the l-lysine content of food and the resulting product |
| US3360374A (en) * | 1965-07-27 | 1967-12-26 | Courtland Lab | Process for making a dietary food product |
| US3970750A (en) * | 1974-10-08 | 1976-07-20 | Sandoz, Inc. | Effervescent potassium chloride composition |
| US4168307A (en) * | 1974-11-08 | 1979-09-18 | Mitsubishi Chemical Industries Limited | N2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof |
| ZA773318B (en) * | 1976-06-18 | 1978-04-26 | I Kleinberg | Means and method for improving natural defenses against caries |
| US4340592A (en) * | 1980-03-14 | 1982-07-20 | Adibi Siamak A | Nutrient compositions and method of administering the same |
| IT1133026B (en) * | 1980-06-30 | 1986-07-09 | Manetti & Roberts Italo Brit | D, L-PYROGLUTAMATE I L-ARGININE-BASED DRESSING WITH TOUCH ACTIVITY AT NEURO-ENDOCRINE LEVEL |
| CH655005A5 (en) * | 1983-02-16 | 1986-03-27 | Sigma Tau Ind Farmaceuti | PHARMACEUTICAL COMPOSITION WITH METABOLIC AND ENERGY ACTION USABLE IN CARDIAC AND VASCULAR THERAPY. |
| US5334617A (en) * | 1984-03-19 | 1994-08-02 | The Rockefeller University | Amino acids useful as inhibitors of the advanced glycosylation of proteins |
| US5034377A (en) * | 1984-11-19 | 1991-07-23 | Montefiore Hospital Association Of Western Pennsylvania | Aqueous nutrient compositions comprising oligopeptides |
| GB8603171D0 (en) * | 1986-02-08 | 1986-03-12 | Howard A N | Dietary product |
| US5032608A (en) * | 1986-09-10 | 1991-07-16 | Dudrick Stanley J | Method and substrate composition for treating atherosclerosis |
| US5248688A (en) * | 1986-09-10 | 1993-09-28 | Dudrick Medical Research Fund I, Ltd. | Method and substrate composition for treating atherosclerosis |
| US4920098A (en) * | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
| US5041429A (en) * | 1988-06-01 | 1991-08-20 | Sanwa Kagaku Kenkyusho Co., Ltd. | Cell activators, circulatory ameliorators and edible compositions |
| DE68905387T2 (en) * | 1988-06-22 | 1993-10-21 | Ajinomoto Kk | Amino acid food compositions. |
| US4954526A (en) * | 1989-02-28 | 1990-09-04 | The United States Of America As Represented By The Department Of Health And Human Services | Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents |
| CA1335361C (en) * | 1989-05-24 | 1995-04-25 | Andrei Z. Budzynski | Thrombus-targeted complexes of plasminogen activator and fibrin fragments |
| US4957938A (en) * | 1989-06-21 | 1990-09-18 | Abbott Laboratories | Nutritional formulation for the treatment of renal disease |
| US5380945A (en) * | 1989-06-21 | 1995-01-10 | Abbott Laboratories | Guanidino compounds as regulators of nitric oxide synthase |
| US5157022A (en) * | 1989-11-22 | 1992-10-20 | Adrian Barbul | Method for reducing blood cholesterol using arginine |
| EP0441119A3 (en) * | 1990-01-09 | 1992-10-14 | Richard D. Levere | The use of l-arginine in the treatment of hypertension and other vascular disorders |
| US5106836A (en) * | 1991-02-22 | 1992-04-21 | Clintec Nutrition Co. | Enteral diet |
| US5171217A (en) * | 1991-02-28 | 1992-12-15 | Indiana University Foundation | Method for delivery of smooth muscle cell inhibitors |
| JP2702322B2 (en) * | 1991-08-08 | 1998-01-21 | フジックス株式会社 | Active amino acid calcium, beverage containing the same, and method for producing the same |
| US5374651A (en) * | 1991-09-27 | 1994-12-20 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives |
| US5262435A (en) * | 1992-02-10 | 1993-11-16 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5221668A (en) * | 1992-02-26 | 1993-06-22 | Abbott Laboratories | Nutritional product for trauma and surgery patients |
| US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
| US5326569A (en) * | 1992-12-23 | 1994-07-05 | Abbott Laboratories | Medical foods for the nutritional support of child/adult metabolic diseases |
| US5523087A (en) * | 1995-02-15 | 1996-06-04 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction |
| AU3221599A (en) * | 1998-04-03 | 1999-10-25 | Daily Wellness Company, The | Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation |
| US6007824A (en) * | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
| KR20010009653A (en) * | 1999-07-12 | 2001-02-05 | 유제경 | Composition for treating sexual dysfunction |
| US6444237B1 (en) * | 2001-09-13 | 2002-09-03 | Pamela A. Heleen | Herbal composition for enhancing sexual response |
-
2002
- 2002-05-30 US US10/157,185 patent/US20050196470A9/en not_active Abandoned
- 2002-06-03 AU AU2002310212A patent/AU2002310212B2/en not_active Expired - Fee Related
- 2002-06-03 KR KR10-2003-7015701A patent/KR20040014540A/en not_active Application Discontinuation
- 2002-06-03 JP JP2003504760A patent/JP2004536822A/en active Pending
- 2002-06-03 WO PCT/US2002/017036 patent/WO2002102163A1/en active Application Filing
- 2002-06-03 EP EP02737273A patent/EP1406496A4/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7229649B2 (en) | Method and composition for improving sexual fitness | |
| CN103784611B (en) | It is a kind of that there is improvement sleep to help to alleviate composition and its application of pressure | |
| AU2002310212B2 (en) | Method and composition for enhancing sexual desire | |
| US20050276839A1 (en) | Appetite satiation and hydration beverage | |
| US20040198754A1 (en) | Composition and method for appetite and craving suppression and mood enhancement | |
| CN101460159B (en) | Fatigue-reducing agent | |
| AU2002310212A1 (en) | Method and composition for enhancing sexual desire | |
| US20060110478A1 (en) | Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction | |
| CN102438642A (en) | Composition comprising green tea extract | |
| CN103402530A (en) | Compositions and methods for treating erectile dysfunction | |
| WO2018112475A1 (en) | Energy compositions and methods | |
| US20060269623A1 (en) | Herbal composition and method of use for promoting erections and treating erectile dysfunction in men | |
| WO2015015149A1 (en) | Dietary supplement | |
| US7371415B1 (en) | Method and composition for improving sexual fitness | |
| US20060110477A1 (en) | Composition and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction | |
| CN113632979A (en) | Four-season health-preserving beverage for men and women and preparation method thereof | |
| KR102180363B1 (en) | An anti-impotence formula comprising black sesame and yeast hydrolysate | |
| JP2008044885A (en) | Composition for oral administration for fatigue prevention and preparation for oral administration for fatigue prevention | |
| JP2000157207A (en) | Functional food | |
| KR100835555B1 (en) | Functional chocolate composition and method for producing thereof | |
| Chopra et al. | Minor Drug Habits of India: Part II | |
| CN114588207A (en) | Composition for improving exercise endurance and promoting recovery after exercise and application thereof | |
| Amagase | A combination of various functional food ingredients as a weight management program: randomized, placebo-controlled, and double-blind human clinical studies | |
| US20220000953A1 (en) | Antihypertensive Composition | |
| CN114098055A (en) | Beverage for improving sub-health for men and women and preparation method thereof |